Showing 6341-6350 of 7326 results for "".
- UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-bimekizumab-shows-joint-and-skin-responses-in-psoriatic-arthritis/2457945/UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy in psor
- Aclaris Initiates Pilot Clinical Trial of ATI-50002 Topical for Vitiligohttps://practicaldermatology.com/news/aclaris-initiates-pilot-clinical-trial-of-ati-50002-topical-for-vitiligo/2457947/Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face. This trial will evaluate the safety, t
- Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCChttps://practicaldermatology.com/news/biofrontera-files-investigational-nda-for-phase-3-trial-of-ameluz-for-bcc/2457948/Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma. The IND filing is in accordance with the advice provided by F
- gel-e Receives US FDA Clearance to Expand its Bandage Product Line for Rx, OTC Usehttps://practicaldermatology.com/news/gel-e-receives-us-fda-clearance-to-expand-its-bandage-product-line-for-rx-otc-use/2457951/The U.S. Food and Drug Administration (FDA) has cleared gel-e Inc.’s adhesive bandage for prescription (Rx) and over-the-counter (OTC) use. This 510(k) clearance expands the Company's label to include the ma
- Allergan's CoolSculpting Treatment Now FDA Approved to Improve Appearance Of Lax Tissue in Double Chinhttps://practicaldermatology.com/news/allergans-coolsculpting-treatment-now-fda-approved-to-improve-appearance-of-lax-tissue-in-double-chin/2457956/The FDA has approved Allergan plc's CoolSculpting treatment for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one tr
- Understanding the Role of Long Strands of RNA in Skin Development, Diseasehttps://practicaldermatology.com/news/understanding-the-role-of-long-strands-of-rna-in-skin-development-disease/2457958/RNA pieces, called “long non-coding RNAs” or “lncRNAs,” help skin cells modulate connective tissue proteins, like collagen, and could represent novel therapeutic targets to promote skin repair, according to researchers from Case Western Reserve University School of Medicin
- FDA Warns that Biotin May Interfere with Lab Test Resultshttps://practicaldermatology.com/news/fda-warns-that-biotin-may-interfere-with-lab-test-results/2457961/Biotin may significantly interfere with certain lab tests and cause "clinically significant incorrect lab test results," the US Food and Drug Administration warns. At least 1 death has been related to biotin interference with laboratory results, FDA officials wrote in a Saf
- AI in Action: New Machine Learning Technique May Enhance Computer-aided Diagnosis of Melanomahttps://practicaldermatology.com/news/ai-in-action-new-machine-learning-technique-may-enhance-computer-aided-diagnosis-of-melanoma/2457963/Researchers at Florida Atlantic University’s College of Engineering and Computer Science have developed a technique using machine learning – a sub-field of artificial intelligence (AI) – that will enha
- New Analysis Provides Reassurance on Biosimilar Safetyhttps://practicaldermatology.com/news/new-analysis-provides-reassurance-on-biosimilar-safety/2457964/And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originators, according to a new analysis in the
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea